The antiarrhythmic activity of amino acid-containing derivatives of 1,4-naphthoquinone

Cover Page

Cite item

Full Text

Abstract

In recent times, the issue of cardiac arrhythmia disturbances has garnered increasing attention from researchers. Pharmacotherapy continues to be the primary method for treating rhythm disturbances; however, its effectiveness is often limited due to the common side effects associated with many antiarrhythmic drugs, among which negative inotropic action plays a significant role. One direction in the development of antiarrhythmic agents involves the targeted search for new drugs among agents with metabolic effects. The aim of this study was to investigate the antiarrhythmic activity using models of occlusion and reperfusion arrhythmias in cats, aconitine arrhythmias in rats, and calcium chloride ventricular fibrillation in rats of five original amino acid-containing derivatives of 1,4-naphthoquinone, synthesized at the Lviv Polytechnic Institute under the guidance of Ph.D. A.P. Kartoflitska. The conducted research indicated that the studied compounds exhibit antiarrhythmic effects. The enhancement of the antiarrhythmic activity occurred primarily in those arrhythmia models where metabolic disorders play a significant role in the pathogenesis.

About the authors

Svetlana M. Napalkova

Saint Petersburg State Chemical and Pharmaceutical University

Author for correspondence.
Email: svetlana.napalkova@pharminnotech.com
ORCID iD: 0000-0002-9216-8673
SPIN-code: 7311-2841

D.Sc. in Biology, Professor, Professor at the Department of Pharmacology and Clinical Pharmacology

Russian Federation, Saint Petersburg

Olga V. Buyuklinskaya

Saint Petersburg State Chemical and Pharmaceutical University

Email: olga.buyklinskaya@pharminnotech.com
ORCID iD: 0000-0002-4453-1079
SPIN-code: 9691-6490

Dr.Med.Sci,  Professor at the Department of Pharmacology and Clinical Pharmacology

Russian Federation, Saint Petersburg

References

  1. Miller O.N., Syrov A.V., Doshchitsin V.L., Pavlova T.V., Tarasov A.V. Clinical guidelines and expert opinion on the use of antiarrhythmic drugs in actual practice // Consilium Medicum. - 2019. - Vol. 21. - N. 5. - P. 43-50. doi: 10.26442/20751753.2019.5.190328. (In Russ).
  2. Jones, B., & Burnand, C. Antiarrhythmic drugs. Anaesthesia & Intensive Care Medicine, 2021; 22(5): 319-323.
  3. Nanasi P.P., Pueyo E., Virag L. Perspectives of Antiarrhythmic Drug Therapy: Disappointing Past, Current Efforts, and Faint Hopes. Frontiers in Pharmacology, 2020; 11: 1116.
  4. A.c. SSSR 1690339. N-(3-khloro-1,4-naftokhinonil-2)-2-D,L-asparaginovaya kislota, proyavlyayushchaya kardiostimuliruyushchie svoistva / A.P. Kartoflitskaya, V.T. Kolesnikov, V.S. Zybin, N.M. Mitrokhin, Yu.V. Burov, N.S. Diogenova, A.A. Guzova; zayavl. 30.03.1990, opubl. 20.09.1999; Byul. № 42. (In Russ).
  5. Marakhovsky Yu.Kh. Clinical evaluation of amino acids as drugs: separate systematized ana-lytical sketches. Recipe. 2012;4(84):124-140. (In Russ).
  6. Shenasa, M., Shenasa, MA., Smith, M. (2020). Class I Antiarrhythmic Drugs: Na+ Channel Blockers. In: Martínez-Rubio, A., Tamargo, J., Dan, G . (eds) Antiarrhythmic Drugs. Current Cardiovascular Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-34893-9_2

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies